CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO


27-December-2011
New Certified Spiking Solutions® from Cerilliant – the nonbenzodiazepine metabolite Zolpidem Phenyl-4-carboxylic acid and a stable-labeled internal standard of the new antiepileptic drug Lacosamide.

Zolpidem phenyl-4-carboxylic Z-007
500 ug/mL in 50:50 Acetonitrile:Water

Zolpidem Phenyl-4-carboxylic acid is the major urinary metabolite of zolpidem, accounting for 51% of an administered dose. Literature references indicate the metabolite can be found in urine for 2-3 days following ingestion of a single therapeutic dose of zolpidem.1 Zolpidem, marketed as Ambien or Stilnox, is a nonbenzodiazepine used for the short-term treatment of insomnia.
 
1. J.H. Lewis and J.H. Vine. “A Simple and Rapid Method for the Identification of Zolpidem Carboxylic Acid in Urine.”  Journal of Analytical Toxicology, Vol. 31, May 2007.

Lacosamide-13C, D3, L-027
100 ug/mL in Acetonitrile

Lacosamide is a new antiepileptic drug approved by the FDA in late 2008 for the treatment of partial-onset seizures and diabetic neuropathic pain. The drug is marketed under the trade name Vimpat®. This internal standard is suitable for lacosamide testing methods by LC/MS or GC/MS for clinical toxicology, forensic analysis, or urine drug testing.



Cerilliant Certified Solution Standards and Certified Spiking Solutions are manufactured to the highest industry standards. We are accredited to ISO Guide 34 and ISO/IEC 17025 & certified to ISO 13485 and ISO 9001. Our quality system also incorporates cGMP and GLP requirements


All New Product Announcements


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn